News
NAFDAC Issues Public Alert on Nivea Roll-On Deodorant Recall Due to Risks of Reproductive Harm, Skin Irritation, and Burns

The National Agency for Food and Drug Administration and Control (NAFDAC) is warning consumers about the recall of Nivea BLACK & WHITE Invisible Roll-On Deodorant, 50ml (marked 48H Protection in African Climate) due to safety concerns.
The product recall is led by the European Union (EU) Rapid Alert System for Dangerous Non-Food Products (RAPEX) in Brussels. The affected batch number is 93529610.
Potential Health Risks
The recalled Nivea roll-on contains a chemical known as 2-(4-tert-Butylbenzyl) propionaldehyde (BMHCA), a substance banned in cosmetic products due to its potential health risks. BMHCA is associated with serious side effects, including:
• Reproductive System Harm: Potential risks to fertility and harm to the health of an unborn child.
• Skin Irritation and Burns: May cause skin damage and irritation to users.
Product Details
• Product Name: Nivea BLACK & WHITE Invisible Roll-On Deodorant, 50ml
• Brand: Nivea
• Batch Number: 93529610
• Bar Code: 42299882
• Manufactured in: Germany
• Category: Cosmetics
Important Actions for the Public
NAFDAC advises importers, distributors, retailers, and consumers to avoid importing, distributing, or using the affected Nivea roll-on with this specific batch number. If you possess this product, please:
Check your roll-on deodorant for the affected batch number and take necessary precautions. Your health and safety are paramount.
• Stop Use Immediately: Discontinue the use or sale of the product.
• Return to NAFDAC: Submit stock to the nearest NAFDAC office.
Healthcare providers and consumers are also encouraged to report any adverse reactions associated with this product to NAFDAC through the following channels:
• Email: pharmacovigilance@nafdac.gov.ng
• Online Reporting: NAFDAC Website
• Med-Safety App: Available for download on Android and iOS stores.